Fifth International Symposium on Sigma-2 Receptors

The Fifth International Symposium on Sigma-2 Receptors: Role in Health and Disease

A Three-Day Virtual Meeting
January 13-15, 2021

In Conjunction with the Society for Neuroscience’s 2021 Global Connectome 

Scientific advances have elucidated the role of the sigma-2 receptor as a regulator of the cellular stress response, and recently as a target of the SARS-CoV-2 virus. Sigma-2 ligands, therefore, may have potential to treat conditions that share pathological disruptions in autophagy, lipid metabolism and related pathways. View pre-recorded presentations by expert speakers from the global sigma-2 community then register to join us on January 13th and 14th for an interactive discussion of the presentations. Then, on January 15th, you are invited to participate in a discussion of the evolving nomenclature surrounding the sigma-2 receptor and its associated proteins. 

In past years, these symposia have sparked constructive debate and led to collaborations resulting in novel developments and new publications, including the Proceedings from the Fourth International Symposium on Sigma-2 Receptors: Role in Health and Disease, which was published in November 2020. Join us in January as we continue our mission of advancing the science of sigma-2.

Thank you for participating

Panel Discussion: Sigma-2 Receptors in CNS Disorders
January 13, 2021
3:30 p.m. Eastern Time

Pre-recorded Presentations

Speakers:

Susan Catalano, Ph.D.
Cognition Therapeutics
Introduction to Symposium and Brief History of sigma-2 receptors

Play Video

Meharvan Singh, Ph.D.
Loyola University Chicago
PGRMC1-mediated BDNF Release as a Key Mechanism to Support Progesterone-induced Brain Protection

Play Video

MartĂ­ Colom Cadena, Ph.D.
University of Edinburgh
TMEM97 Increases in Synapses and is a Potential Binding Partner of Amyloid Beta within Synapses in Human Alzheimer’s Disease

Play Video

Susan Catalano, Ph.D.
Cognition Therapeutics
CT1812, a Selective sigma-2 Allosteric Antagonist for the Treatment of Alzheimer’s Disease: Clinical and Preclinical Progress

Play Video

Nicholas Izzo, Ph.D.
Cognition Therapeutics
The Context-dependent Pharmacology of sigma-2 Receptors in Neurons

Play Video

Jinbin Xu, Ph.D.
Washington University
Single Nuclei mRNA Analysis of PGRMC1 in Postmortem Brains

Play Video
Panel Discussion: Sigma-2 Receptors in Oncology and Diseases of the Periphery
January 14, 2021
3:30 p.m. Eastern Time

Speakers:

Wayne D. Bowen, Ph.D.
Brown University
Sigma-2 Receptor Ligand-Induced Programmed Cell Death Mechanisms in Triple Negative Breast Cancer Cells

Play Video

Aladdin Riad, Ph.D.
University of Pennsylvania
Differential Gene Expression by RNA-seq in sigma-2 Receptor/TMEM97 Knockout Cells and its Role in Complement Activation and Viral Uptake

Play Video

Carmen Abate, Ph.D.
UniversitĂ  degli Studi di Bari
Multifunctional Compounds Targeting sigma Receptors and Potential Therapeutic Exploitations

Play Video

Michael A. Cahill, Ph.D.
Charles Sturt University
The PGRMC Journey from Origin to Destination: Neurobiology Implications

Play Video

Mohammad G. Sabbir, Ph.D.
St. Boniface Hospital Research Centre
Perspectives on PGRMC1-mediated Metabolic Regulation

Play Video

Mary Hamby, Ph.D.
Cognition Therapeutics, Inc.
Targeting sigma-2 Receptors in Dry Age-related Macular Degeneration

Play Video
To view content from the 2019 International Symposium on sigma-2 Receptors: Role in Health and Disease, please click here.
Scroll to Top

Thank you for your interest in Cognition’s publications. A PDF of the poster you are interested in will be made available in accordance with the congress’ embargo policy. Please check back soon. 

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

You are now leaving the Cognition Therapeutics website

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.